These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 3510830)

  • 21. Antithrombotic therapy in cardiac disease. An emerging approach based on pathogenesis and risk.
    Stein B; Fuster V; Halperin JL; Chesebro JH
    Circulation; 1989 Dec; 80(6):1501-13. PubMed ID: 2688970
    [No Abstract]   [Full Text] [Related]  

  • 22. Gene therapy and coronary artery bypass grafting: current perspectives.
    George SJ; Channon KM; Baker AH
    Curr Opin Mol Ther; 2006 Aug; 8(4):288-94. PubMed ID: 16955691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of edifoligide.
    Parolari A; Alamanni F; Tremoli E; Biglioli P
    JAMA; 2006 Apr; 295(13):1513; author reply 1514-5. PubMed ID: 16595751
    [No Abstract]   [Full Text] [Related]  

  • 24. Effect of adjunctive treatment with tirofiban on troponin T elevation during stenting of critically stenosed aortocoronary saphenous vein grafts.
    Kurowski V; Toelg R; Jain D; Richter C; Wiegand UK; Richardt G; Khattab AA
    Am J Cardiol; 2005 Sep; 96(5):681-4. PubMed ID: 16125495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contemporary use of embolic protection devices in saphenous vein graft interventions: insights from the stent of saphenous vein grafts trial.
    Heuser RR
    Catheter Cardiovasc Interv; 2011 Mar; 77(4):594. PubMed ID: 21351235
    [No Abstract]   [Full Text] [Related]  

  • 26. Progression from stenosis to occlusion in the proximal native coronary artery after coronary artery bypass grafting.
    Tanaka A; Ishii H; Oshima H; Shibata Y; Tatami Y; Osugi N; Ota T; Kawamura Y; Suzuki S; Usui A; Murohara T
    Heart Vessels; 2016 Jul; 31(7):1056-60. PubMed ID: 26174429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. One-year coronary bypass graft patency: a randomized comparison between off-pump and on-pump surgery angiographic results of the PRAGUE-4 trial.
    Widimsky P; Straka Z; Stros P; Jirasek K; Dvorak J; Votava J; Lisa L; Budesinsky T; Kolesar M; Vanek T; Brucek P
    Circulation; 2004 Nov; 110(22):3418-23. PubMed ID: 15557371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How should I treat critical stenosis of a saphenous venous graft to the posterior descending artery on the bifurcation site?
    Russo F; De Nittis G; Zerboni SC; Valli P; Galli M; Abdou SM; Sachdeva R
    EuroIntervention; 2014; 9(12):1478-82. PubMed ID: 24755389
    [No Abstract]   [Full Text] [Related]  

  • 29. Is early antithrombotic therapy necessary in bioprosthetic valves?
    Mestres CA; Aramendi JI
    J Thorac Cardiovasc Surg; 2010 Sep; 140(3):724-5; author reply 725-6. PubMed ID: 20723739
    [No Abstract]   [Full Text] [Related]  

  • 30. Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent.
    Zimmermann N; Gams E; Hohlfeld T
    Eur J Cardiothorac Surg; 2008 Jul; 34(1):93-108. PubMed ID: 18448350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antithrombotic therapy in patients receiving saphenous vein coronary artery bypass grafts: a protocol for a systematic review and network meta-analysis.
    Solo K; Martin J; Lavi S; Kabali C; John-Baptiste A; Nevis IF; Choudhury T; Mamas MA; Bagur R
    BMJ Open; 2018 Apr; 8(4):e019555. PubMed ID: 29627809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between paraoxonase activity and late saphenous vein graft occlusion in patients with coronary artery bypass grafting.
    Cagirci G; Cay S; Karakurt O; Yazihan N; Aydin C; Acikel S; Dogan M; Kilic H; Topaloglu S; Aras D; Akdemir R
    Kardiol Pol; 2009 Oct; 67(10):1063-8. PubMed ID: 20017071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distal embolic protection for SVG interventions: can we afford not to use it?
    Shaia N; Heuser RR
    J Interv Cardiol; 2005 Dec; 18(6):481-4. PubMed ID: 16336429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene therapy to prevent occlusion of venous bypass grafts.
    Bhardwaj S; Roy H; Ylä-Herttuala S
    Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):641-52. PubMed ID: 18510482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal therapy for degenerated saphenous vein graft disease.
    Kramer B
    J Invasive Cardiol; 1995; 7 Suppl D():14D-20D. PubMed ID: 10155126
    [No Abstract]   [Full Text] [Related]  

  • 36. [Prevention of thrombosis and thromboembolism after mitral valve bioprosthesis].
    Malinovskiĭ NN; Konstantinov BA; Cherepenin LP; Dzemeshkevich SL; Ivanov AS
    Khirurgiia (Mosk); 1982 Nov; (11):64-8. PubMed ID: 7176405
    [No Abstract]   [Full Text] [Related]  

  • 37. Antithrombotic therapy in peripheral vascular disease.
    Genton E; Clagett GP; Salzman EW
    Chest; 1986 Feb; 89(2 Suppl):75S-81S. PubMed ID: 2935370
    [No Abstract]   [Full Text] [Related]  

  • 38. The use of antithrombotic drugs in artery disease.
    Gallus AS
    Clin Haematol; 1986 May; 15(2):509-59. PubMed ID: 3524934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antithrombotic therapy in valvular heart disease--native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Salem DN; Stein PD; Al-Ahmad A; Bussey HI; Horstkotte D; Miller N; Pauker SG
    Chest; 2004 Sep; 126(3 Suppl):457S-482S. PubMed ID: 15383481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myocardial infarction in saphenous percutaneous intervention: are we really doing our best?
    Lozano I; Rondan J; Avanzas P
    Am Heart J; 2009 Sep; 158(3):e39; author reply e41. PubMed ID: 19699850
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.